Company Financials
Trillium Therapeutics Inc. Financials
Canadian dollar
business
Trillium Therapeutics Inc. Company Profile
Main Stock Listing
TSX: TRIL
Market Capitalization C$2.30 Billion as of Nov. 1, 2021
Market Cap History
Valuations Metrics as of Jan. 25, 2025
| Trailing PE | |
| Forward PE | -24.30 |
| Price to Sales TTM | C$16550.90 |
| Price to Book MRQ | C$ |
| Enterprise to Revenue | 14883.54 |
| Enterprise to EBITDA | -36.07 |
Financial Reports as of Sep. 30, 2021
Financials
| Fiscal Year Ends | 2020-12-31 |
| Most Recent Quarter | 2021-09-30 |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets TTM | -20.28% |
| Return on Equity TTM | -27.03% |
Income Statement
| Revenue TTM | C$148,000 |
| Revenue per Share TTM | C$0.00 |
| Quarterly Revenue Growth | -100.00% |
| Gross Profit TTM | C$148,000 |
| EBITDA | C$None |
| Net Income to Common TTM | C$-59,346,000 |
| Diluted EPS TTM | C$-0.70 |
| Quarterly Earnings Growth YoY | % |
Balance Sheet
| Total Cash MRQ | C$None |
| Total Cash per Share MRQ | C$ |
| Total Debt MRQ | C$ |
| Total Debt to Equity MRQ | 0.00 |
| Current Ratio MRQ | 33.31 |
| Book Value per Share MRQ | C$1.77 |
Cash Flow
| Operating Cash Flow TTM | C$-16,612,000 |
| Levered Free Cash Flow TTM | C$-59,346,000 |
TRIL Stock Info as of Jan. 25, 2025
Stock Statistics
| Shares Outstanding | 84,780,000 |
| Float Shares | None |
| Avg 10 Volume | 88,187 |
| Avg 30 Volume | None |
| Shares Short | None |
| Short Ratio | |
| Short % of Shares | % |
| % Held by Insiders | % |
| % Held by Institutions | % |
Stock Price Summary
| Beta | |
| Fifty Two Week Low | C$7.48 |
| Fifty Two Week High | C$24.62 |
| Fifty Two Week Change | % |
| Day 50 MA | C$22.18 |
| Day 200 MA | C$14.96 |
Dividends and Splits
| Forward Annual Dividend Rate | C$ |
| Forward Annual Dividend Yield | % |
| Trailing Annual Dividend Rate | C$ |
| Trailing Annual Dividend Yield | % |
| Payout Ratio | % |
| Dividend Date | |
| Ex Dividend Date | |
| Last Split Factor | |
| Last Split Date |